New Technology– category –
-
The Multispecific Antibody Revolution: Reshaping CDMOs for Next-Gen Biologics
BioSpace USA Overview The rapid advancement of multispecific antibody therapeutics is fundamentally transforming the service delivery models and development architectures of Contract Development and Manufacturing Organizations (CDMOs). T... -
UBC Bolsters AI-Driven Drug Discovery and Protein Design with New Research Chairs
UBC Medicine Canada Overview The University of British Columbia's Faculty of Medicine has appointed three world-renowned scientists as Eddie Goldenberg Research Chairs to accelerate breakthroughs in AI-driven protein design, drug deliver... -
BRD4-Targeting PROTAC Nanoassemblies Dramatically Enhance FLASH Radiotherapy, Achieving Robust Tumor Suppression
PMC USA Overview New research reveals that BRD4-targeting PROTAC nanoassemblies (APF) significantly amplify the anti-tumor efficacy of ultra-high dose rate FLASH radiotherapy (FLASH-RT). By efficiently delivering the BRD4 degrader ARV-77... -
AbbVie’s Etentamig: A Next-Generation Bispecific Engager Set to Redefine Multiple Myeloma Treatment
Fierce Biotech USA Overview AbbVie has announced positive Phase 3 clinical trial results for etentamig, a second-generation bispecific T-cell engager, in patients with relapsed/refractory multiple myeloma (RRMM). Targeting BCMA and CD3, ... -
Democratizing Advanced Immunotherapy: BiTE Therapies Expand into Community Cancer Centers
American Oncology Network USA Overview Bispecific T-cell Engager (BiTE) therapy represents a significant breakthrough in cancer treatment, now experiencing expanding adoption within community oncology facilities across the United States.... -
Advanced TME Models Unlock Novel Strategies for Enhanced ADC Therapy
Journal for ImmunoTherapy of Cancer USA Overview A recent study published in the Journal for ImmunoTherapy of Cancer modeled how the tumor immune microenvironment (TME) impedes the delivery and efficacy of antibody-drug conjugates (ADCs)... -
FDA Grants Fast Track Designation to Four Novel Cancer Therapeutics, Accelerating Development for Urgent Needs
Targeted Oncology USA Overview In August 2026, the U.S. FDA granted Fast Track designation to four novel oncology drugs, significantly accelerating their development and review processes. These include Erasca Inc.'s ERAS-0015 (pancreatic... -
AI and Advanced Pharma Tech Converge: Insilico’s INS018_055 Achieves Clinical Success
MDPI Switzerland Overview Artificial intelligence and machine learning are revolutionizing pharmaceutical R&D by integrating with advanced technologies like pharmacogenomics and organ-on-a-chip systems. AI-designed drugs, such as Ins... -
Generative AI & Quantum Computing Converge to Revolutionize Inverse Design for Molecules and Materials
SEMICON Taiwan Taiwan Overview Generative AI is enabling a transformative "inverse design" approach, directly generating molecular and material structures with desired properties, thereby fundamentally reshaping drug discovery and materi... -
Nature Communications: AI-Powered RCDO Framework Integrates Molecular Generation and Experimental Feedback to Accelerate Drug Discovery
Nature Communications Unknown Overview A groundbreaking closed-loop reinforcement learning framework, Rapid Compound Directed Optimization (RCDO), has been unveiled in a new Nature Communications paper for drug discovery. RCDO seamlessly...
